Protagonist Therapeutics, Inc.
Bear Case (25th pct.)
-86.8% vs price
Base Case (Median)
-83.5% vs price
Bull Case (75th pct.)
-79.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $29.27 | -81.5% | High (40%) |
| PE Comparable | $22.92 | -85.5% | Medium (25%) |
| Graham Number | $14.97 | -90.6% | Medium (40%) |
| EV/FCF | $41.58 | -73.8% | Medium (20%) |
Based on 4 out of 8 methods, PTGX appears overvalued at the current price of $158.62. The base case fair value of $26.10 implies 83.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.